HAZ Stock Overview
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Haemonetics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$79.50 |
| 52 Week High | US$87.00 |
| 52 Week Low | US$65.00 |
| Beta | 0.36 |
| 1 Month Change | 6.71% |
| 3 Month Change | 7.43% |
| 1 Year Change | 7.43% |
| 3 Year Change | 40.71% |
| 5 Year Change | 0.89% |
| Change since IPO | 280.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| HAZ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.9% | 1.7% | 1.7% |
| 1Y | 7.4% | -7.7% | 2.3% |
Return vs Industry: HAZ exceeded the German Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: HAZ exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| HAZ volatility | |
|---|---|
| HAZ Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HAZ has not had significant price volatility in the past 3 months.
Volatility Over Time: HAZ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 3,034 | Chris Simon | www.haemonetics.com |
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system.
Haemonetics Corporation Fundamentals Summary
| HAZ fundamental statistics | |
|---|---|
| Market cap | €4.09b |
| Earnings (TTM) | €118.19m |
| Revenue (TTM) | €1.19b |
34.6x
P/E Ratio3.4x
P/S RatioIs HAZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HAZ income statement (TTM) | |
|---|---|
| Revenue | US$1.27b |
| Cost of Revenue | US$582.96m |
| Gross Profit | US$687.22m |
| Other Expenses | US$560.65m |
| Earnings | US$126.57m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 2.49 |
| Gross Margin | 54.10% |
| Net Profit Margin | 9.97% |
| Debt/Equity Ratio | 92.3% |
How did HAZ perform over the long term?
See historical performance and comparison